Patents by Inventor Tetsuya Suhara
Tetsuya Suhara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240083893Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.Type: ApplicationFiled: May 8, 2023Publication date: March 14, 2024Applicant: National Institutes for Quantum and Radiological Science and TechnologyInventors: Makoto HIGUCHI, Tetsuya SUHARA, Masahiro MARUYAMA, Meiei CHO, Hitoshi SHIMADA
-
Patent number: 11667628Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.Type: GrantFiled: September 16, 2021Date of Patent: June 6, 2023Assignee: NATIONAL INSTITUTES FOR QUANTUM AND RADIOLOGICAL SCIENCE AND TECHNOLOGYInventors: Makoto Higuchi, Tetsuya Suhara, Masahiro Maruyama, Meiei Cho, Hitoshi Shimada
-
Publication number: 20220133698Abstract: The present invention provides an ?-synuclein aggregate binding agent that has high binding selectivity for an ?-synuclein aggregate. The ?-synuclein aggregate binding agent contains a compound represented by a formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof: in the formula (I), R1 and R2 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; the ring A is a benzene or pyridine ring; the ring B is represented by the following formula (i) or (ii): R4 and R5 are each independently selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl.Type: ApplicationFiled: January 24, 2020Publication date: May 5, 2022Inventors: Makoto Higuchi, Maiko Ono, Tetsuya Suhara, Meiei Cho
-
Publication number: 20220056020Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.Type: ApplicationFiled: September 16, 2021Publication date: February 24, 2022Inventors: Makoto HIGUCHI, Tetsuya SUHARA, Masahiro MARUYAMA, Meiei CHO, Hitoshi SHIMADA
-
Publication number: 20210275696Abstract: The purpose of the present invention is to provide a technique for imaging the brain of a live animal and application of the technique. A radiolabeled dibenzoazepine derivative, which shows excellent brain parmeability, high receptor selectivity and high quantitativity, is used for imaging a live animal body. A dibenzoazepine derivative is used for treating a disease in which hM4D receptor or hM3D receptor participates. Further, a radiolabeled dibenzoazepine derivative is used for imaging an axonal end which is innervated by a nerve cell.Type: ApplicationFiled: June 21, 2019Publication date: September 9, 2021Applicant: National Institutes for Quantum and Radiological Science and TechnologyInventors: Takafumi MINAMIMOTO, Yuji NAGAI, Bin JI, Naohisa MIYAKAWA, Makoto HIGUCHI, Tetsuya SUHARA
-
Publication number: 20200262829Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof. wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and [Formula 3] represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.Type: ApplicationFiled: February 21, 2020Publication date: August 20, 2020Inventors: Makoto Higuchi, Tetsuya Suhara, Masahiro Maruyama, Meiei Cho, Hitoshi Shimada
-
Patent number: 10604516Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof. wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and ??[Formula 3] represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.Type: GrantFiled: December 21, 2012Date of Patent: March 31, 2020Assignee: National Institutes for Quantum and Radiological Science and TechnologyInventors: Makoto Higuchi, Tetsuya Suhara, Masahiro Maruyama, Meiei Cho, Hitoshi Shimada
-
Patent number: 10335503Abstract: The present invention provides a compound represented by formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof. (In the formula, each of A and Z independently represents CO, SO or SO2; each of X and Y independently represents S or O; each of R1-R4 independently represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group or a halogen group; each R5 independently represents an alkyl group, an alkenyl group, an alkynyl group or a halogen group; and n represents an integer of 0-4.) This compound is capable of specifically binding to an AMPA receptor, and shows extremely high brain uptake.Type: GrantFiled: July 5, 2016Date of Patent: July 2, 2019Assignee: Public University Corporation Yokohama City UniversityInventors: Takuya Takahashi, Tomoyuki Miyazaki, Tetsuya Suhara, Makoto Higuchi, Meiei Cho
-
Patent number: 10041954Abstract: The purpose of the present invention is to provide: a biomarker for psychiatric and neurological disorders, in particular, a biomarker for diagnosing psychiatric and neurological disorders; and a test kit and test method for psychiatric and neurological disorders. The inventors discovered that there is a significant increase in the concentration of free ? immunoglobulin chains and free ? immunoglobulin chains in the blood samples from patients with psychiatric and neurological disorders. Consequently, the present invention provides a biomarker for psychiatric and neurological disorders that includes at least one selected from the group consisting of free ? immunoglobulin chains, free ? immunoglobulin chains, and fragments thereof. Using this biomarker for psychiatric and neurological disorders enables the psychiatric and neurological disorders to be easily tested and diagnosed with the blood samples from the subjects.Type: GrantFiled: March 18, 2014Date of Patent: August 7, 2018Assignee: RESVO INC.Inventors: Arata Ohnishi, Takafumi Minamimoto, Tetsuya Suhara
-
Publication number: 20180200391Abstract: The present invention provides a compound represented by formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof. (In the formula, each of A and Z independently represents CO, SO or SO2; each of X and Y independently represents S or O; each of R1-R4 independently represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group or a halogen group; each R5 independently represents an alkyl group, an alkenyl group, an alkynyl group or a halogen group; and n represents an integer of 0-4.) This compound is capable of specifically binding to an AMPA receptor, and shows extremely high brain uptake.Type: ApplicationFiled: July 5, 2016Publication date: July 19, 2018Applicant: Public University Corporation Yokohama City UniversityInventors: Takuya Takahashi, Tomoyuki Miyazaki, Tetsuya Suhara, Makoto Higuchi, Meiei Cho
-
Publication number: 20180120328Abstract: The purpose of the present invention is to provide: a biomarker for psychiatric and neurological disorders, in particular, a biomarker for diagnosing psychiatric and neurological disorders; and a test kit and test method for psychiatric and neurological disorders. The inventors discovered that there is a significant increase in the concentration of free ? immunoglobulin chains and free ? immunoglobulin chains in the blood samples from patients with psychiatric and neurological disorders. Consequently, the present invention provides a biomarker for psychiatric and neurological disorders that includes at least one selected from the group consisting of free ? immunoglobulin chains, free ? immunoglobulin chains, and fragments thereof. Using this biomarker for psychiatric and neurological disorders enables the psychiatric and neurological disorders to be easily tested and diagnosed with the blood samples from the subjects.Type: ApplicationFiled: July 10, 2017Publication date: May 3, 2018Inventors: Arata OHNISHI, Takafumi MINAMIMOTO, Tetsuya SUHARA
-
Patent number: 9382303Abstract: This invention relates to a vaccine for preventing or treating tautopathy, comprising a vector, as an active ingredient, comprising a nucleic acid encoding a mutant tau protein linked to a secretion signal sequence, wherein the vaccine is capable of inducing an antibody against an (optionally phospholylated) tau protein in a subject in a more sustained manner compared with a case where the mutant tau protein is administered directly.Type: GrantFiled: December 30, 2014Date of Patent: July 5, 2016Assignees: KYOTO UNIVERSITY, NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCESInventors: Haruhisa Inoue, Hiroki Takeuchi, Ryosuke Takahashi, Makoto Higuchi, Bin Ji, Tetsuya Suhara
-
Publication number: 20160131663Abstract: The purpose of the present invention is to provide: a biomarker for psychiatric and neurological disorders, in particular, a biomarker for diagnosing psychiatric and neurological disorders; and a test kit and test method for psychiatric and neurological disorders. The inventors discovered that there is a significant increase in the concentration of free ? immunoglobulin chains and free ? immunoglobulin chains in the blood samples from patients with psychiatric and neurological disorders. Consequently, the present invention provides a biomarker for psychiatric and neurological disorders that includes at least one selected from the group consisting of free ? immunoglobulin chains, free ? immunoglobulin chains, and fragments thereof. Using this biomarker for psychiatric and neurological disorders enables the psychiatric and neurological disorders to be easily tested and diagnosed with the blood samples from the subjects.Type: ApplicationFiled: March 18, 2014Publication date: May 12, 2016Inventors: Arata OHNISHI, Takafumi MINAMIMOTO, Tetsuya SUHARA
-
Publication number: 20160045625Abstract: A compound selected from the group consisting of compounds represented by the formulas below or pharmaceutically acceptable salt thereof is useful in PET imaging for AMPA receptor.Type: ApplicationFiled: April 2, 2014Publication date: February 18, 2016Inventors: Norihito Oi, Noboru Yamamoto, Michiyuki Suzuki, Yosuke Nakatani, Tetsuya Suhara, Meiei Cho, Toshimitsu Fukumura, Makoto Higuchi, Takafumi Minamimoto, Jun Maeda, Masaki Tokunaga, Yuji Nagai
-
Publication number: 20150266937Abstract: This invention relates to a vaccine for preventing or treating tautopathy, comprising a vector, as an active ingredient, comprising a nucleic acid encoding a mutant tau protein linked to a secretion signal sequence, wherein the vaccine is capable of inducing an antibody against an (optionally phospholylated) tau protein in a subject in a more sustained manner compared with a case where the mutant tau protein is administered directly.Type: ApplicationFiled: December 30, 2014Publication date: September 24, 2015Applicants: National Institute of Radiological Sciences, Kyoto UniversityInventors: Haruhisa INOUE, Hiroki TAKEUCHI, Ryosuke TAKAHASHI, Makoto HIGUCHI, Bin JI, Tetsuya SUHARA
-
Publication number: 20150239878Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof. wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and ??[Formula 3] represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.Type: ApplicationFiled: December 21, 2012Publication date: August 27, 2015Inventors: Makoto Higuchi, Tetsuya Suhara, Masahiro Maruyama, Meiei Cho, Hitoshi Shimada
-
Patent number: 8945576Abstract: This invention relates to a vaccine for preventing or treating tautopathy, comprising a vector, as an active ingredient, comprising a nucleic acid encoding a mutant tau protein linked to a secretion signal sequence, wherein the vaccine is capable of inducing an antibody against an (optionally phosphorylated) tau protein in a subject in a more sustained manner compared with a case where the mutant tau protein is administered directly.Type: GrantFiled: January 11, 2011Date of Patent: February 3, 2015Assignees: Kyoto University, National Institute of Radiological SciencesInventors: Haruhisa Inoue, Hiroki Takeuchi, Ryosuke Takahashi, Makoto Higuchi, Bin Ji, Tetsuya Suhara
-
Publication number: 20130189289Abstract: This invention relates to a vaccine for preventing or treating tautopathy, comprising a vector, as an active ingredient, comprising a nucleic acid encoding a mutant tau protein linked to a secretion signal sequence, wherein the vaccine is capable of inducing an antibody against an (optionally phosphorylated) tau protein in a subject in a more sustained manner compared with a case where the mutant tau protein is administered directly.Type: ApplicationFiled: January 11, 2011Publication date: July 25, 2013Applicants: NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES, KYOTO UNIVERSITYInventors: Haruhisa Inoue, Hiroki Takeuchi, Ryosuke Takahashi, Makoto Higuchi, Bin Ji, Tetsuya Suhara
-
Publication number: 20100111838Abstract: Brain-localizing polypeptides carrying a reactive group for linking to a molecule that does not have brain-localizing activity were successfully produced by introducing at least two lysine residues into cyclized polypeptides having a brain-localizing motif sequence. These polypeptides have improved metabolic stability compared to conventional brain-localizing polypeptides, and can efficiently translocate desired molecules into the brain.Type: ApplicationFiled: February 27, 2008Publication date: May 6, 2010Applicants: Proteus Sciences Co., Ltd, National Institute of Radiological SciencesInventors: Tomohiro Nakajo, Hirotaka Hara, Kazumasa Yamamoto, Hiromi Suzuki, Makoto Sawada, Tetsuya Suhara, Makoto Higuchi, Terushi Haradahira, Hin Ki
-
Publication number: 20100055036Abstract: The present invention relate to a method for monitoring a response to a therapy on a mammal having a neurodegenerative or neuroinflammatory disorder. According to a preferred embodiment, the method comprising the steps of: a) imaging the mammal using a radio-labeled peripheral benzodiazepine receptor ligand; b) administrating in the mammal at least one anti-amyloid or anti-neuroinflammatory agent; c) imaging the mammal of step b) using a radio-labeled peripheral benzodiazepine receptor ligand; and d) detecting the level of CNS neuroinflammation by the signals from the radio-labeled peripheral benzodiazepine receptor ligand.Type: ApplicationFiled: March 12, 2008Publication date: March 4, 2010Applicant: National Institute of Radiolotgical SciencesInventors: Tetsuya Suhara, Kazutoshi Suzuki, Makoto Higuchi, Ming-Rong Zhang, Jun Maeda, Bin Ji